A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 2, 2006, Pages 131-136

  Vezina, Heather E ^a   Henry, Keith ^a,b   Ravindran, G D ^c   Kurpad, Anura V ^d   Raj, Tony D S ^d   Fox, Kathy ^a   Weller, Dennis ^a   Brundage, Richard C ^e   Cavert, Winston ^a   Balfour Jr , Henry H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^d St John's Academy of Health Sciences   (India)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bioequivalence; Generic antiretrovirals; Lamivudine; Nevirapine; Pharmacokinetics; Zidovudine

Indexed keywords

GENERIC DRUG; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INDIAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TABLET; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE TRANSMISSION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHYSIOLOGY; SERODIAGNOSIS;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; INDIA; LAMIVUDINE; NEVIRAPINE; TABLETS; THERAPEUTIC EQUIVALENCY; ZIDOVUDINE;

EID: 33645290009     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000199098.95967.ab     Document Type: Article

References (29)

1. Joint United Nations Program on HIV/AIDS and World Health Organization. Epidemiological fact sheets on HIV/AIDS and sexually transmitted infections: India. Geneva: UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance, 2004 update. Available at: http://www.unaids.org/EN/ Geographical+Area/by+country/india.asp. Accessed October 20, 2005.
2. Joint United Nations Program on HIV/AIDS. 2004 report on the global AIDS epidemic 2004: fourth global report. Geneva: Joint United Nations Program on HIV/AIDS (UNAIDS), 2004. Available at: http://www. unaids.org/bangkok2004/report.html. Accessed October 20, 2005.
3. World Health Organization. Antiretroviral drugs for treating pregnant women and prevention of HIV infection in infants: guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Geneva: World Health Organization, 2004. Available at: http://www.who.int/hiv/pub/mtct/guidelines/en/. Accessed October 20, 2005.
4. Merchant RH, Damania K, Gilada IS, et al. Strategy for preventing vertical transmission of HIV: Bombay experience. Indian Pediatr. 2001;38:132-138.
5. Kunte A, Misra V, Paranjape R, et al. HIV seroprevalence and awareness about AIDS among pregnant women in rural areas of Pune district, Maharashtra, India. Indian J Med Res. 1999;110:115-122.
6. Frost KR. Ensuring the safety of HIV/AIDS generics. Lancet. 2005;365: 1290-1291.
7. World Health Organization. WHO statement on removal of two AIDS medicines from list of prequalified products. Geneva: World Health Organization, June 17, 2004. Available at: http://www.who.int/mediacentre/news/ statements/2004/statement_aidsprequal/en. Accessed October 20, 2005.
8. World Health Organization. Three AIDS medicines will be removed from prequalification list this week. Geneva: World Health Organization, August 4, 2004. Available at: http://www.who.int/mediacentre/news/releases/ 2004/pr53/en/. Accessed October 20, 2005.
9. World Health Organization. Two Cipla AIDS medicines back on WHO prequalification list. Geneva: World Health Organization, November 30, 2004. Available at: http://www.who.int/mediacentre/news/releases/2004/ pr87/en/. Accessed October 20, 2005.
10. US Food and Drug Administration. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. Rockville, MD: United States Food and Drug Administration Center for Drug Evaluation and Research, July 2002. Available at: http://www.fda. gov/cder/guidance/3615fnl.htm. Accessed October 20, 2005.
11. National Institute of Allergy and Infectious Diseases, National Institutes of Health. Division of AIDS table for grading severity of adult adverse experiences. Bethesda, MD: National Institute of Allergy and Infectious Diseases, National Institutes of Health, August 1992. Available at: http:// aactg.s-3.com/members/ainfosit.htm. Accessed October 20, 2005.
12. Fan B, Stewart JT. Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J Pharm Biomed Anal. 2002;28:903-908.
13. US Food and Drug Administration. Statistical approaches to establishing bioequivalence. Rockville, MD: United States Food and Drug Administration Center for Drug Evaluation and Research, January 2001. Available at: http://www.fda.gov/cder/guidance/3616fnl.htm. Accessed October 20, 2005.
14. Viramune (nevirapine) tablets prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2003.
15. Epivir (lamivudine) tablets prescribing information. Middlesex, UK: GlaxoSmithKine Pharmaceuticals 2003.
16. Retrovir (zidovudine) Tablets prescribing information. GlaxoSmithKline, Research Triangle Park, NC; 2003.
17. Palombi L, Germano P, Liotta G, et al. HAART in pregnancy: safety, effectiveness, and protection from viral resistance: results from the DREAM cohort [abstract 67]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston. In: Programs and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health; 2005.
18. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217-228.
19. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229-240.
20. Beckerman KP. Mothers, orphans, and prevention of paediatric AIDS. Lancet. 2002;359:1168-1169.
21. Walgreens Pharmacy. Combivir 150 mg/300 mg tablets. Available at: http://www.walgreens.com/library/finddrug/druginfol.jsp?particularDrug= Combivir&id=14087. Accessed October 20, 2005.
22. Walgreens Pharmacy. Viramune 200 mg tablets. Available at: http:// www.walgreens.com/library/finddrug/druginfo1.jsp?particularDrug= Viramune&id=14694. Accessed October 20, 2005.
23. Clinton Foundation Programs HIV/AIDS Initiative. Available at: http:// www.clintonfoundation.org/pdf/arv-price-list-030705.pdf. Accessed October 20, 2005.
24. Laurito TL, Santagada V, Caliendo G, et al. Nevirapine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. J Mass Spectrom. 2002;37:434-441.
25. Narang VS, Lulla A, Malhotra G, et al. Pharmacokinetic profiling and bioequivalence evaluation of 2 lamivudine tablet formulations after single oral administration in healthy human Indian volunteers. J Acquir Immune Defic Syndr. 2005;38:566-569.
26. Narang VS, Lulla A, Malhotra G, et al. Bioequivalence evaluation of two marketed brands of stavudine 40 mg capsules in healthy human South African volunteers. Pharmacol Res. 2004;50:511-516.
27. Kumarasamy N, Solomon S, Chaguturu SK, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS. 2003;17:2267-2269.
28. Pujari SN, Patel AK, Naik E, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr. 2004;37:1566-1569.
29. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1 infected adults in Cameroon: open-label multicentre trial. Lancet. 2004;364:29-34.